about
Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selectionGene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancerRelevance of tumor-infiltrating lymphocytes in breast cancerUtility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus StatementSerum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapyPIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical dataClinical application of the 70-gene profile: the MINDACT trialDeciphering clonality in aneuploid breast tumors using SNP array and sequencing data.Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer.Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.Prediction of breast cancer prognosis using gene set statistics provides signature stability and biological context.Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancerThe AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international groupPIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancerTargeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacyValidation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.Identification of novel Ras-cooperating oncogenes in Drosophila melanogaster: a RhoGEF/Rho-family/JNK pathway is a central driver of tumorigenesis.RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment.Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer.A three-gene model to robustly identify breast cancer molecular subtypesChallenges in breast cancer clinical trial design in the postgenomic era.Breast cancer gene expression profiling: clinical trial and practice implications.CD73: A potential biomarker for anti-PD-1 therapyThe Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE".Uncovering the genomic heterogeneity of multifocal breast cancer.Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trialThe use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response.RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint InhibitorsQuality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.CD4⁺ follicular helper T cell infiltration predicts breast cancer survivalSomatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancerCD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
P50
Q24605762-01955626-819F-4B13-A00A-C350D60FF9E1Q24652481-1D879759-6225-4BA3-8ABA-E7BA0DF3F0BEQ26795598-66D24D61-7F25-43F8-812B-B60CE725EB22Q27020973-AB6CFD67-AE8B-452D-A111-7E3C860F8F8DQ27853328-359C3E98-CEE7-4F61-A680-756491C722B1Q28235277-08C2318D-FC44-4B6B-8E73-E13B3D9EC5E3Q28247338-BC404E09-CFC3-45E4-9EB1-16DCBB30697DQ28267891-7EDC2B0B-B14D-4778-93D2-2A7F1CE5E679Q30856576-726CB1AC-F09A-49CA-8774-AEC0AE9ABCD7Q33337206-AEF68B8B-9CC9-4D22-8ED2-ABA100D037F5Q33361574-B9B3BF3F-EAEC-434A-BBC5-44D3A523B3E5Q33423263-01E3AA33-F0AE-41F9-B4C9-E6D03A4578C0Q33586739-1CEEF2C8-5560-4A0F-834B-4AC11EB43416Q33637070-A61D711D-BFF9-4442-80D3-B8CC81EB27C7Q33854251-80E4E31E-7CBC-419D-A97B-7B93EA89BB82Q33933172-38A9255E-2097-48E0-A84A-64E25765568DQ34342897-43C03B4F-E3B0-42CC-881A-18DC39BD743FQ34542434-0BF5EF5E-772F-44F3-BF57-40C23041C90FQ34550649-59008F45-7F14-44D7-BC95-51EC7C9499A3Q34563697-960F6764-4700-48B7-8E9D-605C477508C5Q35060075-BA242EF1-827C-4A4F-8F50-CD8645EB622CQ35218182-F648E7D9-FB4E-41FB-A77A-A0B80AB94746Q35655229-9769830B-4DF6-41DE-A5D1-95E553A73CA5Q35733734-1453D83C-2B27-4D8C-BC96-C3C5DC698574Q35769036-7637AC7F-174D-454D-A386-D0533A1AFB8EQ35997214-01301DFA-5312-425A-B94E-4BBCC1EFDED2Q36050579-888AEB36-5C73-4536-8BD2-156E36DDA6DEQ36107945-6BB134E3-84AB-4B3B-B7FA-DA629CBCF738Q36233893-AC20207E-F0A9-4D96-866F-12151101F0F4Q36404728-2EC758DB-39FE-4851-8C42-A1CFC2D2C509Q36449290-E80A28C0-1FD4-4D9F-9825-95FC4470A5D4Q36557582-78BEF80D-6CBA-4D4C-877C-F928C2A165EAQ36613514-E17C01CB-1647-4801-972B-0A9B13A43F2AQ36616213-15A966AB-F3C0-4AA6-BAEC-5E5FB46942BEQ36646429-24071ECE-4C8B-4E06-8F5D-F2B134DA6E9EQ36693087-B1868A99-5D37-4126-BCF8-088EAE4372EBQ36935214-651BE3F5-E336-4996-9EAE-28F093DB57CDQ36966923-5F66BF4C-514D-489B-802D-4BD3963FD180Q36976208-61DBC46B-3735-497E-8392-7A79AB12B4E3Q36991010-9A508CE0-71A1-4724-94CE-44131796B5C9
P50
description
consultant oncologist and researcher
@en
onderzoeker
@nl
հետազոտող
@hy
name
Sherene Loi
@ast
Sherene Loi
@en
Sherene Loi
@es
Sherene Loi
@nl
Sherene Loi
@sl
type
label
Sherene Loi
@ast
Sherene Loi
@en
Sherene Loi
@es
Sherene Loi
@nl
Sherene Loi
@sl
prefLabel
Sherene Loi
@ast
Sherene Loi
@en
Sherene Loi
@es
Sherene Loi
@nl
Sherene Loi
@sl
P21
P31
P496
0000-0001-6137-9171